Table 2.
Multivariable models of CAV1 levels in relation to recurrences in all patients and stratified by BMI, waist circumference, and invasive tumor size.
| Breast cancer event |
||||
|---|---|---|---|---|
| HR | (95% CI) | |||
| CAV1 stroma strong | 1.26 | 0.92–1.73 | ||
| TBSAS | 1.10 | 1.04–1.17 | ||
| Age, years | 1.00 | 0.98–1.01 | ||
| pT2/3/4 | 2.16 | 1.55–3.02 | ||
| ALNI | 1.43 | 0.98–2.09 | ||
| Grade III | 1.76 | 1.19–2.61 | ||
| ER+ | 1.16 | 0.65–2.05 | ||
| Chemotherapy | 0.94 | 0.56–1.59 | ||
| Radiotherapy | 0.75 | 0.55–1.03 | ||
| Trastuzumab | 0.72 | 0.38–1.39 | ||
| Tamoxifen | 0.64 | 0.45–0.90 | ||
| Aromatase Inhibitor | 0.68 | 0.46–1.00 | ||
| BMI ≥ 25 kg/m2 | BMI < 25 kg/m2 | |||
| HR | (95% CI) | HR | (95% CI) | |
| CAV1 stroma strong | 0.85 | 0.53–1.37 | 1.92 | 1.22–3.02 |
| TBSAS | 1.12 | 1.03–1.22 | 1.07 | 0.97–1.17 |
| Age, years | 1.01 | 0.99–1.03 | 0.98 | 0.96–1.01 |
| pT2/3/4 | 1.99 | 1.29–3.09 | 2.43 | 1.40–4.19 |
| ALNI | 1.44 | 0.87–2.38 | 1.43 | 0.81–2.53 |
| Grade III | 1.46 | 0.85–2.52 | 2.44 | 1.37–4.33 |
| ER+ | 1.06 | 0.48–2.34 | 1.18 | 0.50–2.76 |
| Chemotherapy | 1.13 | 0.58–2.23 | 0.65 | 0.29–1.47 |
| Radiotherapy | 0.75 | 0.48–1.15 | 0.74 | 0.47–1.18 |
| Trastuzumab | 0.93 | 0.42–2.07 | 0.51 | 0.16–1.61 |
| Tamoxifen | 0.79 | 0.48–1.28 | 0.56 | 0.34–0.92 |
| Aromatase Inhibitor | 0.80 | 0.48–1.35 | 0.58 | 0.31–1.06 |
| Waist ≥ 80 cm | Waist < 80 cm | |||
| HR | (95% CI) | HR | (95% CI) | |
| CAV1 stroma strong | 1.02 | 0.70–1.48 | 2.25 | 1.16–4.36 |
| TBSAS | 1.12 | 1.05–1.20 | 1.07 | 0.92–1.25 |
| Age, years | 1.00 | 0.98–1.02 | 0.98 | 0.95–1.01 |
| pT2/3/4 | 1.79 | 1.22–2.61 | 4.53 | 2.11–9.73 |
| ALNI | 1.48 | 0.96–2.27 | 1.79 | 0.78–4.12 |
| Grade III | 1.57 | 1.01–2.44 | 3.15 | 1.34–7.42 |
| ER+ | 0.97 | 0.52–1.83 | 7.22 | 1.07–48.74 |
| Chemotherapy | 1.03 | 0.58–1.85 | 0.64 | 0.18–2.33 |
| Radiotherapy | 0.71 | 0.49–1.01 | 0.78 | 0.40–1.55 |
| Trastuzumab | 0.89 | 0.45–1.76 | No event | |
| Tamoxifen | 0.60 | 0.40–0.90 | 0.60 | 0.29–1.26 |
| Aromatase Inhibitor | 0.72 | 0.46–1.12 | 0.40 | 0.16–1.02 |
| pT2/3/4 | pT1 | |||
| HR | (95% CI) | HR | (95% CI) | |
| CAV1 stroma strong | 0.75 | 0.41–1.35 | 1.61 | 1.09–2.38 |
| TBSAS | 1.08 | 0.98–1.19 | 1.10 | 1.02–1.19 |
| Age, years | 1.00 | 0.97–1.03 | 1.00 | 0.97–1.02 |
| ALNI | 1.19 | 0.65–2.18 | 1.61 | 1.00–2.60 |
| Grade III | 1.32 | 0.74–2.36 | 2.33 | 1.37–3.96 |
| ER+ | 0.89 | 0.33–2.42 | 1.42 | 0.65–3.10 |
| Chemotherapy | 1.26 | 0.59–2.69 | 0.67 | 0.31–1.44 |
| Radiotherapy | 0.96 | 0.57–1.61 | 0.68 | 0.46–1.01 |
| Trastuzumab | 0.56 | 0.23–1.35 | 1.14 | 0.41–3.15 |
| Tamoxifen | 0.85 | 0.42–1.71 | 0.53 | 0.35–0.82 |
| Aromatase Inhibitor | 0.56 | 0.29–1.10 | 0.83 | 0.50–1.38 |
Missing data for four patients for at least one variable.
TBSAS - Time between surgery and staining.